INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 731–TA–1369–1372 (Final)]

Fine Denier Polyester Staple Fiber From China, India, Korea, and Taiwan: Supplemental Schedule for the Subject Investigations


ACTION: Notice.


General information concerning the Commission may also be obtained by accessing its internet server (https://www.usitc.gov). The public record for these investigations may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov.

SUPPLEMENTARY INFORMATION: Effective November 6, 2017, the Commission established a general schedule for the conduct of the final phase of its investigations on fine denier polyester staple fiber (“fine denier PSF”) from China, India, Korea, and Taiwan, following preliminary determinations by the U.S. Department of Commerce (“Commerce”) that imports of fine denier PSF from China, India, Korea, and Taiwan were subsidized by the governments of China and India. To date, Commerce has issued final affirmative countervailing duty determinations with respect to fine denier PSF from China, India, and Taiwan, and most recently final affirmative antidumping duty determinations with respect to China, India, Korea, and Taiwan. The Commission, therefore, is issuing a supplemental schedule for its antidumping duty investigations on imports of fine denier PSF from China, India, Korea, and Taiwan.

The Commission’s supplemental schedule is as follows: The deadline for filing supplemental party comments on Commerce’s final determinations is June 12, 2018; the staff report in the final phase of these investigations will be placed in the nonpublic record on June 21, 2018; and a public version will be issued thereafter.

Supplemental party comments may address only Commerce’s final antidumping duty determinations regarding fine denier PSF from China, India, Korea, and Taiwan. These supplemental final comments may not contain new factual information and may not exceed five (5) pages in length.

For further information concerning these investigations see the Commission’s notice cited above and the Commission’s Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A and C (19 CFR part 207).

Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.21 of the Commission’s rules.

By order of the Commission.

Issued: June 1, 2018.

Lisa Barton, Secretary to the Commission.

[FR Doc. 2018–12169 Filed 6–5–18; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Richard Hauser, M.D.: Decision and Order

On September 26, 2017, the Acting Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (DEA), issued an Order to Show Cause to Richard Hauser, M.D. (Registrant), of Clear Lake, Iowa. The Show Cause Order proposed the revocation of Registrant’s DEA Certificate of Registration No. BH2140692 “pursuant to 21 U.S.C. 824(a)(5).” Government Exhibit (GX) 2


To Government’s Request for Final Agency Action (RFAA), at 1. For the same reason, the Order also proposed the denial of “any pending application to modify or renew such registration.” Id.

With respect to the Agency’s jurisdiction, the Show Cause Order alleged that Registrant is the holder of Certificate of Registration No. BH2140692, pursuant to which he is authorized to dispense controlled substances as a practitioner in schedules II through V, at the registered address of Hauser Clinic Consultation Services, 308 14th Street, Clear Lake, Iowa. Id.

Regarding the substantive ground for the proceeding, the Show Cause Order alleged that on April 28, 2017, the Office of the Inspector General for the U.S. Department of Health and Human Services (HHS) notified Registrant of his “mandatory exclusion from Medicare is an independent ground for revoking a DEA registration pursuant to 21 U.S.C. 824(a)(5).” Id. The Order further contended that, although Registrant’s underlying conviction is “unrelated to [Registrant’s] handling of controlled substances, DEA has nevertheless found that the underlying conviction forming the basis for a registrant’s exclusion from participating in federal health care programs need not involve controlled substances for revocation under 21 U.S.C. 824(a)(5).” Id. (citations omitted).

The Show Cause Order notified Registrant of (1) his right to request a hearing on the allegations or to submit a written statement in lieu of a hearing, (2) the procedure for electing either option, and (3) the consequence for failing to elect either option. Id. at 2–3 (citing 21 CFR 1301.43). The Show Cause Order also notified Applicant of his right to submit a corrective action plan. Id. at 3–4 (citing 21 U.S.C. 824(c)(2)(C)).

The Government states that on October 4, 2017, a DEA Diversion Investigator (DI) served Registrant with a copy of the Show Cause Order. RFAA, at 3 (citing Declaration of DI attached as GX 4). Specifically, a DI assigned to the St. Louis Field Division’s Des Moines Resident Office stated in a declaration that he was advised by Registrant’s Attorney that Registrant could be served at his residence at 2310 20th Street, SW,